Key result
First-line treatment with FEC 50 or FEC 75 resulted in significantly higher overall response rates (44.6% and 44.7%) compared to epirubicin alone (30.6%) in advanced breast cancer.
Why the study?
Does FEC 50 or FEC 75 improve response rates compared to epirubicin alone in patients with advanced breast cancer?
Population
412 patients with advanced breast cancer receiving first treatment, stratified by presence of bone…
Comparison
FEC 50 or FEC 75 vs Epirubicin alone 75 mg/m2
Design
RCT, Randomized, stratified according to whether or not there were bone…
Loading...
Supports FEC combinations over epirubicin monotherapy for higher response rates; confirms benefit of anthracycline-based polychemotherapy in advanced breast cancer.
RCT (n=412)
Yes
Does FEC 50 or FEC 75 improve response rates compared to epirubicin alone in patients with advanced breast cancer?
Absolute Event Rate: 44.7% vs 30.6%
p-value: p=0.0006
Combination chemotherapy with FEC 50 or FEC 75 improves overall response rates compared to epirubicin monotherapy in advanced breast cancer, though without significant differences in overall survival.
A 1991 study conducted an RCT in Advanced breast cancer (n=412). FEC 50 and FEC 75 vs. Epirubicin alone 75 mg/m2 was evaluated on Overall response rate (p=0.0006). First-line treatment with FEC 50 or FEC 75 resulted in significantly higher overall response rates (44.6% and 44.7%) compared to epirubicin alone (30.6%) in advanced breast cancer.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: